ERBB2 and neoplasm: By tumor subtypes, pN0(i+) and pN1mi rates were 11.08% (996/8988) and 34.72% (996/2869) among all patients and among patients with involved lymph nodes and Luminal-A-like tumors, 12.64% (149/1178) and 24.96% (149/597) among patients with Luminal-B-HER2-negative-like tumors, 8.88% (68/766) and 23.45% (68/290) among patients with ER-positive/HER2-positive tumors, 8.89% (40/450) and 19.42% (40/206) among patients with ER-negative/HER2-positive tumors, and 6.42% (70/1091) and 20.71% (70/338) among patients with triple-negative tumors.